RxDoctor Payments DataLook up a doctor →

Lisa Clough

Family · Pueblo, CONPI 1841459690

Payments from drug & device makers

$7,108in general payments, 2019–2025

Across 436 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$615
  • AstraZeneca$564
  • Pfizer$512
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$309
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,096100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,108 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$59,161
Medicare patients
197
Services billed
4,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$187,598
MounjaroTirzepatide131$172,334
FarxigaDapagliflozin Propanediol63$52,231
EliquisApixaban48$42,562
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$40,523
JanuviaSitagliptin Phosphate34$31,780
TrulicityDulaglutide26$25,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog123$15,699
LinzessLinaclotide14$15,047
XareltoRivaroxaban18$14,446
Tresiba Flextouch U-200Insulin Degludec13$8,192
SymbicortBudesonide/Formoterol Fumarate21$7,845
Tresiba Flextouch U-100Insulin Degludec16$7,390
Levemir FlexpenInsulin Detemir18$5,189
Novolog FlexpenInsulin Aspart25$4,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$192$197,676157 claims
Novo NordiskOzempic$1,285$187,598164 claims
AstraZenecaFarxiga, Symbicort$564$60,07684 claims
PfizerEliquis$512$42,56248 claims
GSKTrelegy Ellipta$615$40,52343 claims
MerckJanuvia$15$31,78034 claims
AbbVieLinzess, Synthroid$1,187$16,86943 claims
Johnson & JohnsonXarelto$222$14,44618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →